IFNG and hepatocellular carcinoma: Another completed phase I clinical trial (NCT01974661) conducted by Rizell et al. evaluated the safety and feasibility of a mature-DC vaccine (also known as ilixadencel) co-activated with Toll-like receptor (TLR) 3 and 7/8 agonists and IFN-γ, either alone or combined with the molecular-targeted drug sorafenib, in treating 17 patients with advanced primary HCC [41].